Adial Pharmaceuticals (ADIL)

Overall impact
B (74)

Commentary

Adial Pharmaceuticals is a strong overall performer. With a 'B' rating of 74.0 for overall impact (88th percentile compared to all companies), Adial Pharmaceuticals ranks 178th out of 585 industry peers, behind Biogen, Amgen, Regeneron Pharmaceuticals and 174 others, and ahead of Grifols, Ionis Pharmaceuticals, Gilead Sciences and 404 others. On top material causes for Adial Pharmaceuticals's industry (Pharmaceuticals & Biotech), Adial Pharmaceuticals performs well in Access to Affordable Healthcare (96.1 score), Child and Maternal Health (93.6), Reduced Use of tobacco (95.5) and 4 other causes where it received an 'A' score and performs poorly in Humane Treatment of Animals (38.6 score), Disaster Readiness and Effective Aid (40.0) and Reduced Green House Gas Emissions (35.7).
Impact
Cause ADIL
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2010
Employees
5
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Va, United States
Share classes
ADIL
Description
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Glen Allen, Virginia.
Material causes
Ethos considers the following causes material for Adial Pharmaceuticals, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.